Evidence map›Paper›PMID 30309763›Full record

Trial reportThe Journal of molecular diagnostics : JMD2018

Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment.

Fang Wei, Charles M Strom, Jordan Cheng, Chien-Chung Lin, Ching-Yun Hsu, Guy W Soo Hoo, David Chia, Yong Kim, Feng Li, David Elashoff and 7 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of molecular diagnostics : JMD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Longitudinal Monitoring ofFrontiers in oncology · 2020
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Fang WeiSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Charles M StromSchool of Dentistry, University of California, Los Angeles, Los Angeles, California. Electronic address: cstrom@mednet.ucla.edu.
Jordan ChengSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Chien-Chung LinDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ching-Yun HsuSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Guy W Soo HooDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
David ChiaSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Yong KimSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Feng LiSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
David ElashoffSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Tristan GrognanSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Michael TuSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Wei LiaoSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
Rena XianDepartment of Pathology and Molecular Medicine, University of California, Los Angeles, Los Angeles, California.
Wayne W GrodyDepartment of Pathology and Molecular Medicine, University of California, Los Angeles, Los Angeles, California.
Wu-Chou SuDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: sunnysu@mail.ncku.edu.tw.
David T W WongSchool of Dentistry, University of California, Los Angeles, Los Angeles, California.
University of California, Los Angeles · USNational Cheng Kung University Hospital · TW

Funding

EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer AssessmentU01CA233370 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., HSU, WILLIAM · 2018 to 2025
$8.0M
Clinical Utility of Salivary ExRNA Biomarkers for Gastric Cancer DetectionUH3TR000923 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2015 to 2017
$2.7M
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH3CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., SOO HOO, GUY · 2019 to 2021
$1.2M
Clinical Utility of Salivary ExRNA Biomarkers for Gastric Cancer DetectionUH2TR000923 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2013 to 2014
$996k
Ultra-short circulating tumor DNA (uctDNA) for liquid biopsy of non-small cell lung cancerR21CA239052 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, FENG, WONG, DAVID T · 2019 to 2020
$373k
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH2CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., DAS, KINGSHUK · 2017 to 2018
$368k
NCATS NIH HHS UH2 TR000923NCATS NIH HHS UH3 TR000923NCI NIH HHS R21 CA239052NCI NIH HHS U01 CA233370NCI NIH HHS UH2 CA206126NCI NIH HHS UH3 CA206126
6 · The paper itself

Abstract

Previously, we detected circulating tumor DNA that contained two EGFR mutations (p.L858R and exon19 del) in plasma of patients with late-stage non-small-cell lung carcinoma (NSCLC) using the electric field-induced release and measurement (EFIRM) platform. Our aim was to determine whether EFIRM technology can detect these mutations in patients with early-stage NSCLC. Prospectively, 248 patients with radiographically determined pulmonary nodules were recruited. Plasma was collected before biopsy and histologic examination of the nodule. Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or exon19 delEGFR mutations. Plasma samples were available from 44 patients: 23 with biopsy-proven benign pulmonary nodules and 21 with stage I or II adenocarcinoma (12 p.L858R and 9 exon19 delEGFR variants). Samples were analyzed for the EGFR mutations using the EFIRM platform. Assay sensitivity was 92% for p.L858R (11 of 12 samples positive) and 77% for exon19 del (7 of 9 samples positive). Specificity was 91% with two false-positive results in 23 patients with EGFR-positive nodules and 95% for the entire 44-patient series. Concordance was 100% with identical mutations discovered in plasma and nodule biopsy. The EFIRM platform is able to noninvasively detect two EGFR mutations in individuals with early-stage NSCLC.

Indexed as

ElectricityEarly Detection of CancerFemaleHumansLiquid BiopsyLung NeoplasmsMale

Identifiers

PMID30309763
PMCPMC6198245
OpenAlexW2897229272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.